Pacira Pharma (PCRX) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Clear Street Starts Forgent Power Solutions (FPS) at Buy
Pacira BioSciences Reports First Quarter 2022 Financial Results
May 4, 2022 8:00 AM EDT-- First quarter revenue of $158 million, up 33% over prior year --
-- Strong topline performance delivers net income and significantly positive adjusted EBITDA --
-- Conference call today at 8:30 a.m. ET --
TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2022.
First Quarter 2022 Financial Highlights
Total revenues of $158.0... More


